BRIEF—New real-world evidence supports case for Entresto

Novartis has presented new real-world data from the CHAMP-HF registry comparing Entresto (sacubitril/valsartan) patients to patients not taking Entresto.

Interim data show that chronic heart failure patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by a commonly-used score.

The firm says there were statistically significant improvements in symptom frequency and quality of life.

The results were presented as part of a late-breaking session at the European Society of Cardiology Heart Failure (ESC-HF) Congress in Vienna, Austria.